Related Experiment Videos
Methyl-CpG-binding domain 2: a protective role in bladder carcinoma.
Yong Zhu1, Margaret R Spitz, Hui Zhang
1Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Cancer
|April 28, 2004
Summary
High MBD2 protein expression is linked to a reduced risk of bladder cancer. This protective effect was more pronounced in women, older individuals, and heavier smokers, suggesting MBD2
Area of Science:
- Epigenetics and Cancer Biology
- Molecular Oncology
Background:
- Methyl-CpG-binding domain 2 (MBD2) protein plays a role in epigenetic gene regulation.
- MBD2's function in demethylation is debated, but reduced MBD2 mRNA is seen in tumors.
- Previous studies noted decreased MBD2 expression in various tumor types.
Purpose of the Study:
- To investigate the association between MBD2 expression and bladder carcinoma risk.
- To determine if MBD2 levels correlate with susceptibility to bladder cancer.
Main Methods:
- Case-control study design.
- RNA extracted from peripheral blood lymphocytes of 98 bladder cancer patients and 135 controls.
- MBD2 expression quantified using real-time quantitative reverse transcription-polymerase chain reaction (RT-qPCR).
Main Results:
- High MBD2 expression significantly reduced bladder carcinoma risk (OR, 0.43; 95% CI, 0.21-0.90).
- A significant trend of decreasing risk with increasing MBD2 expression quartiles was observed (P < 0.05).
- Protective effects were stronger in women, older individuals, and heavier smokers.
Conclusions:
- This study provides the first evidence for a protective role of MBD2 against bladder carcinoma risk.
- MBD2 expression may counteract age-related, gender-related, and smoking-induced hypermethylation.
- Further research is needed to elucidate the molecular mechanisms underlying MBD2's protective role.